These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 16713364

  • 1. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT, Sharma AM.
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [Abstract] [Full Text] [Related]

  • 2. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD.
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 4. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B, Fonseca V.
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [Abstract] [Full Text] [Related]

  • 5. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A.
    Acta Med Indones; 2006 Jul; 38(3):160-6. PubMed ID: 17119268
    [Abstract] [Full Text] [Related]

  • 6. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N, Walcher D.
    Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
    [Abstract] [Full Text] [Related]

  • 7. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG, Hele DJ, Birrell MA.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):101-9. PubMed ID: 16458290
    [Abstract] [Full Text] [Related]

  • 9. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thulé PM, Sutliff RL, Hart CM.
    Vascul Pharmacol; 2007 Jun 08; 46(6):456-62. PubMed ID: 17337254
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
    Luconi M, Cantini G, Serio M.
    Steroids; 2010 Jun 08; 75(8-9):585-94. PubMed ID: 19900469
    [Abstract] [Full Text] [Related]

  • 11. PPARgamma in endothelial cells influences high fat diet-induced hypertension.
    Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ.
    Am J Hypertens; 2005 Apr 08; 18(4 Pt 1):549-56. PubMed ID: 15831367
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F, Caglayan E, Hsueh WA.
    Endocrinol Metab Clin North Am; 2006 Sep 08; 35(3):561-74, ix. PubMed ID: 16959586
    [Abstract] [Full Text] [Related]

  • 13. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J, Morales M, Caelles C.
    Diabetes; 2007 Jul 08; 56(7):1865-71. PubMed ID: 17416798
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE.
    Clin Exp Pharmacol Physiol; 2009 May 08; 36(5-6):478-86. PubMed ID: 19673929
    [Abstract] [Full Text] [Related]

  • 15. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ, Usher MG, Mortensen RM.
    Circ Res; 2008 Feb 15; 102(3):283-94. PubMed ID: 18276926
    [Abstract] [Full Text] [Related]

  • 16. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V, Viswanathan P.
    Curr Opin Investig Drugs; 2006 Oct 15; 7(10):891-7. PubMed ID: 17086933
    [Abstract] [Full Text] [Related]

  • 17. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.
    Sarafidis PA, Lasaridis AN.
    Am J Hypertens; 2006 Jun 15; 19(6):646-53. PubMed ID: 16733240
    [Abstract] [Full Text] [Related]

  • 18. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 19. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
    Gacka M, Adamiec R, Dobosz T, Szymaniec S, Bednarska-Chabowska D.
    Przegl Lek; 2004 Apr 14; 61(12):1436-9. PubMed ID: 15850344
    [Abstract] [Full Text] [Related]

  • 20. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA.
    Arterioscler Thromb Vasc Biol; 2006 Jan 14; 26(1):28-40. PubMed ID: 16239592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.